Financial Disclosure

Stockholm – September 17, 2026 -- Telefonaktiebolaget LM Ericsson repurchased Class B shares on Nasdaq Stockholm between September 7 and September 17, 2026, pushing its total treasury stock holding to 107,518,663 Class B shares.

Ericsson executes buyback under a SEK 15 billion program launched in April 2026

The repurchases form part of a share buyback program of up to SEK 15,000,000,000 that Ericsson announced on September 17, 2026. The program runs from September 17, 2026, through September 17, 2026, at the latest.

Goldman Sachs Bank Europe executed all trades on Nasdaq Stockholm

Goldman Sachs Bank Europe SE carried out all acquisitions on behalf of Ericsson during the reporting period, in compliance with the EU Market Abuse Regulation (No 596/2014) and its Safe Harbour Regulation supplement of March 2016.

Dublin – September 17, 2026 -- Davion Healthcare Plc has secured admission of a £30 million senior secured bond to trading on the Vienna MTF, operated by Wiener Börse AG, giving the Irish healthcare group a dedicated capital pool to fund acquisitions.

Bond carries 10.5% fixed coupon over five-year term

The bond, issued through financing subsidiary Davion Healthcare Finance Ltd, commenced in August 2026 and carries a fixed annual coupon of 10.5%. It trades under ISIN GB00BTH2SB89, with a denomination of £100,000 per unit.

Proceeds target acquisitions across five healthcare segments

Davion plans to deploy the capital toward acquiring established, cash-generative businesses in medical devices, diagnostics, medical distribution, healthcare technology and healthcare services. Proceeds are released on an acquisition-by-acquisition basis through Davion Healthcare Finance Ltd, with security granted over each acquired asset.

Pasadena – September 17, 2026 -- Sophia Space has entered a $300 million financing framework with aerospace leasing specialist SLI to fund a 10-satellite edge computing constellation, applying asset-leasing models long used in aviation and energy to orbital infrastructure for the first time.

SLI will purchase and lease 10 satellites under a fixed-payment structure

Under the non-binding letter of support, SLI will buy the satellites from Sophia and lease them to end-users on fixed monthly or quarterly payments, aligning the financing timeline with Sophia's build and deployment schedule. The arrangement supports purchase and deployment of 10 Sophia TILE spacecraft through a long-term operating lease spanning the satellites' expected useful lives, with mission launches planned as early as 2028.

Seoul – September 17, 2026 -- Johnson & Johnson reported that its RYBREVANT (amivantamab-vmjw) plus chemotherapy combination extended median overall survival to 34.3 months in patients with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer, compared with 27.9 months for chemotherapy alone, according to final data from the Phase 3 PAPILLON study.

Combination therapy nearly doubles historical survival benchmarks

The result marks the longest reported median overall survival for this patient population, which has historically faced a five-year survival rate of just 8 percent and a median overall survival ranging from 16 to 24 months. EGFR exon 20 insertion mutations account for approximately 12 percent of all EGFR mutations and have proven difficult to treat with existing targeted therapies.

Toronto – September 17, 2026 -- Franco-Nevada Corporation has agreed to a A$200 million (approximately $144 million) follow-on financing package with Minerals 260 Limited to advance the Bullabulling Gold Project in Western Australia, lifting its total backing of the project to an aggregate A$420 million (approximately $300 million).

The package comprises a A$170 million (approximately $122 million) gross royalty acquisition and a A$30 million (approximately $22 million) equity subscription as lead order in a future Minerals 260 capital raise.

Hong Kong – September 17, 2026 -- Akeso, Inc. (9926.HK) reported that its bispecific antibody ivonescimab reduced the risk of death by 27% compared with Merck's pembrolizumab in a Phase III trial of PD-L1-positive non-small cell lung cancer (NSCLC), with results presented as a Late-Breaking Abstract at the 2026 World Conference on Lung Cancer (WCLC).

Ivonescimab extends median survival to 30.8 months in head-to-head trial

In the intention-to-treat population of the HARMONi-2 study (AK112-303), patients treated with ivonescimab monotherapy achieved a median overall survival (OS) of 30.8 months versus 22.6 months for pembrolizumab (HR=0.73; 95% CI: 0.57–0.95; P=0.009). The data cutoff was September 17, 2026, with a median follow-up of 36 months and 234 OS events recorded. Professor Caicun Zhou, principal investigator and IASLC President, is scheduled to deliver the full oral presentation on September 15.

Austin, Texas – September 17, 2026 -- Oracle Corporation (NYSE: ORCL) confirmed that Executive Chair and Chief Technology Officer Larry Ellison has cancelled his 10b5-1 trading plan to sell company stock, halting a scheduled divestment before any shares changed hands.

Ellison cancels stock sale plan with zero shares sold

Oracle stated no stock was sold under the now-terminated 10b5-1 plan. The company added that Ellison currently has no other arrangements in place to sell any of his Oracle shares.

Los Angeles – September 17, 2026 -- Adventist Health White Memorial and Adventist Health White Memorial Montebello generate more than $1.2 billion in annual economic activity and support approximately 5,500 jobs across Los Angeles County, according to a new study.

Study quantifies hospitals' role as economic anchors serving 2.4 million residents

The analysis, conducted by the Los Angeles County Economic Development Corporation (LAEDC), examined the two hospitals' functions as healthcare providers, employers, and community anchors. Combined, they serve more than 2.4 million residents across their primary and secondary service areas.

Newark, Del. – September 17, 2026 -- Xanh Entertainment Inc. is pursuing a $2.5 million seed funding round to scale EscapeSquid, its platform linking virtual stationary cycling with fitness studios, local events and destination travel.

Xanh Entertainment targets $2.5 million to build fitness-to-travel infrastructure

John Phung, Founder and CEO of Xanh Entertainment Inc., said the proposed seed round is intended to fund technology development and partnerships across fitness, hospitality and travel sectors. The capital would support a model designed to move participants from at-home virtual rides into studio classes, local experiences, regional events and destination travel.

Quebec – September 17, 2026 -- Devonian Health Group Inc. (TSXV: GSD) (OTCQB: DVHGF) expects its common shares and warrants to begin trading on NYSE American LLC as early as September 17, 2026, under the ticker symbols "DHGR" and "DHGR WS."

Devonian pursues dual listing tied to underwritten public offering

The proposed NYSE American listing is connected to an underwritten public offering of Devonian's common shares and warrants. The company will retain its existing listing on the TSX Venture Exchange and has reserved the symbol "DHGR" there, with plans to later change its TSXV ticker from "GSD" to "DHGR."

Listing remains contingent on NYSE American's final authorization

Trading commencement on NYSE American depends on market conditions and final approval of Devonian's listing application, as well as the company's continued compliance with exchange rules.